Randy Trice is a man with a straightforward demeanor, and he’s made his mark at Alphanumeric Systems Inc., where each day brings new challenges. He leads this global company by having plans for every situation; empowering employees to execute those goals efficiently (and always over-deliver); while maintaining great relationships all along the way – which helps them stay motivated when things get tough!

Trice’s decades of experience in business consulting and executive management started with a bachelor’s degree from Texas A&M University, where he focused primarily on finance.

As CEO, Trice leads the way in transforming the patient experience and improving brand loyalty for pharmaceutical customers. He is passionate about using technologies like AI to improve healthcare services around the world while making life easier through digital transformation solutions at Alphanumeric’s global contact centers—all aimed toward one goal: improving the human experience.

Trice is an expert at establishing operational excellence and transforming conceptual strategies into growth markets. He’s made sure that the company operates with a high level of customer satisfaction, maintaining its near-perfect CSAT score for several years now as well. Since joining Alphanumeric, Trice has successfully led Alphanumeric to grow 3x in revenue and into 8 new countries in less than 5 years: and he’s far from finished.

Chairman, CEO Roundtable on Cancer
Chairman of the Board, President and Chief Executive Officer, Amgen, Inc.

Robert A. Bradway is Amgen’s chairman and chief executive officer. Bradway became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.

Prior to joining Amgen, he was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.

He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university. He is the chairman of the CEO Roundtable on Cancer, a non-profit organization comprised of executives founded to bring solutions to cancer treatment and prevention. He is a member of the American Heart Association CEO Roundtable on Cancer, which is helping the Association meet its goal of improving the cardiovascular health of all Americans.  He is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors.

Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.

Peter Sandor Vice President, Head of Oncology Therapeutic Area Marketing Strategy. In this role, Peter provides commercial leadership for project’s within the oncology therapeutic area and plays an integral role in the expansion of Astellas’s presence in oncology.

Peter has 20 years of progressive marketing experience. He was recently the Vice President, Global Marketing Oncology at Amgen responsible for the successful realization of the commercial potential for Amgen’s oncology assets. Prior to Amgen, he has held different positions at Bayer Healthcare, including Head of Strategy and Portfolio Management Specialty Medicine, Commercial Development and Life Cycle Management Global Oncology. He also worked for Berlex Laboratories as the lead of the global launch team for a key oncology compound, and held multiple marketing roles with Schering AG in Germany and Hungary.

Peter started his career in bench research as a scientific advisor of the Hungarian Academy. He received his MDS Marketing and MBA from Middlesex University, London and Faculty of Business and Economy, University of Pécs, Hungary, and his MD from University of Pécs, Hungary.

Dave Fredrickson was appointed EVP, Global Head Oncology Business Unit in October 2017 and is responsible for driving growth and maximizing commercial performance of the global oncology and haematology portfolio within AstraZeneca. In addition, he plays a critical leadership role in setting the Oncology portfolio and product strategy for the organisation.

Prior to this role, Dave served as President of AstraZeneca K.K. in Japan, and Vice President, Specialty Care for AstraZeneca in the United States, spanning oncology, infection disease, and neuroscience medicines. Dave joined AstraZeneca from Roche/Genentech in 2014, where he was Business Unit Manager, Oncology in Spain and held growing commercial responsibilities in strategy, marketing and sales in the US.  He also served for nine years at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy. He has served as Vice Chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan and was a member of the Board of the Japan Pharmaceutical Manufacturers Association (JPMA).  He is a graduate of Georgetown University (DC) in Government.

Dr. Robert Brown is Chief Executive Officer of B&C International (BCI).  Throughout his career, Dr. Brown has spent significant time solving problems and cultivating key high level relationships in the United States and on the continents of Africa, Asia and Europe.  As BCI’s visionary, he continues to strategically support company platform development, global growth and client engagements.

He also serves as an Ambassador for the CEO Roundtable on Cancer’s Going for Gold initiative, which is focused on improving health equity, education, navigation, and access to care in partnership with academic institutions.

Dr. Brown speaks frequently on race relations, emerging markets and international strategy and was recognized by the Washington Post as a World Class Power Broker.  Recently retiring from the boards of the NCAA, Duke Energy, Wachovia Corporation, Wake Forest University Baptist Medical Center and Sonoco Products Company, Dr. Brown is a strong supporter of youth, education and non-violent programs.  Dr. Brown currently serves on the boards of High Point University, Boston University, Virginia Union University, National Urban League, Horatio Alger Association and the Richard Nixon Foundation.

Numerous colleges, universities and national organizations have honored Brown. He holds ten honorary doctorate degrees and six national achievement awards. He has also been honored as a recipient of the Horatio Alger Association of Distinguished Americans Award, the Small Business Administration’s Lifetime Achievement Award, the United Way of Greater High Point’s 2002 Alexis de Tocqueville Society Award, The High Point Enterprise 2005 Citizen of the Year Award, the U.S. Department of Commerce’s Minority Business Development Agency’s 2006 Abe Venable Legacy Award for Lifetime Achievement, the U.S. Department of Commerce Minority Business Development Agency’s 2007 National Director’s Legacy Award for Lifetime Achievement and the National Urban League’s 2009 Collins Award.

Robert joined Bayer as SVP, Head of Oncology TA in October 2015.  He has more than 27 years of bio-pharmaceutical experiences most of which has been spent in specialty areas, mainly Oncology.  Before joining Bayer, Robert was the SVP, Global Oncology with Bristol-Myers Squibb and co-led the Oncology Disease Strategy team with direct responsible to set the vision, strategy, and execution for the Immuno-Oncology (I-O) Franchise at BMS.

Robert currently serves on the Louisiana Tech College of Business Administration Advisory Board and is a member of AACR and BioNJ.  He, his wife and two sons reside in Robbinsville, New Jersey.

David M. Epstein, Ph.D., is a biopharmaceutical leader and executive who has successfully led R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings for over 20 years. Epstein is a Founder of Black Diamond Therapeutics and took the Company public on the NASDQ Global Market in January 2020, having cumulatively raised over $400 million in private and public financing.

Prior to his appointment as Black Diamond’s President and CEO, Epstein was Vice Dean, Innovation & Entrepreneurship, at Duke-NUS Medical School, Singapore, establishing the Centre for Technology & Development and building a pipeline of venture-backed companies. Epstein was Associate Professor in the Cancer & Stem Cell Biology Program at Duke-NUS where he established a research program focused on the role of defective mRNA splicing in cancer. This work resulted in the simultaneous discovery of splicing-derived shared tumor antigens and their cognate TCR pairs, which has led to the founding of PairX Bio, a venture-backed Precision Immuno-Oncology company. Previously, he was Chief Scientific Officer at OSI Pharmaceuticals, acquired by Astellas Pharma for over $4 billion in 2010, and was a founder and senior executive at Archemix Corp. Epstein’s R&D teams have progressed more than a dozen novel agents through clinical development in oncology, cardiovascular disease, and retinal degeneration.

Epstein earned a Ph.D. in Biochemistry at Brandeis University and led a joint post-doctoral fellowship in protein structure-function and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. He received a B.Sc. in Chemistry from Lewis & Clark College.

Mr. Boers joined Boehringer Ingelheim in 1998 in Belgium, and advanced through various roles in corporate and operating units, including Corporate Vice President, Marketing and Sales Effectiveness, Country Managing Director for France and Human Pharma head of a European region consisting of mid-sized countries. Mr. Boers came to the U.S. in 2016 as Senior Vice President of the Specialty Care Franchise, and since January 2017, has led the U.S. Human Pharma business. He earned a master’s degree in social and economic history from the University of Nijmegen (Netherlands) and an MBA from the University of Texas.

Christoph Schweizer is CEO of Boston Consulting Group (BCG), elected May 2021. Prior to this role, he was BCG’s chairman for Central and Eastern Europe and the Middle East. He has also served as a member of the firm’s Executive and Operating Committees since 2014.

Christoph is a member of several leading organizations, including the Business Roundtable and the World Economic Forum’s International Business Council. For the past three years, INvolve People recognized Christoph as a HERoes Advocate Executive Role Model for his work with Women@BCG related to the hiring, promotion, and retention of women.

Throughout his career, Christoph has supported clients in health care and private equity, and across industries in major transformational programs such as digital transformations and post-merger integrations. He is a passionate supporter of a wide range of social impact activities, in particular related to sustainability and fighting climate change.

Christoph joined BCG in 1997, first in Munich, and then New York from 2007 to 2012, before returning to Munich. He received an MBA from University of Texas at Austin’s McCombs School of Business and holds a BA from WHU – Otto Beisheim School of Management in Koblenz.

Michael “Mike” Mahoney is Chief Executive Officer of Boston Scientific Corporation and Chairman of the company’s Board of Directors. Boston Scientific is a global medical technology leader with approximately $12.7 billion in annual revenue and commercial representation in more than 130 countries. Under Mike’s leadership, Boston Scientific is delivering on its mission to transform lives through innovative medical solutions that improve the health of patients around the world. The company’s team of more than 45,000 global employees reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation and urology, and women’s health.

Since joining Boston Scientific, Mike has focused the company on addressing the needs of the evolving healthcare landscape by driving improvements to patient outcomes and increasing healthcare economic efficiency and access. Under his leadership, Boston Scientific has brought many transformational medical devices to market while creating significant value to its shareholders.

Mike’s career spans more than 25 years of success building market-leading medical device, capital equipment and healthcare IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics (MD&D) division of Johnson & Johnson.

Prior to joining Johnson & Johnson, Mike was President and Chief Executive Officer of Global Healthcare Exchange (GHX). For the first 12 years of his career, Mike advanced through a series of leadership roles at General Electric Medical Systems, including General Manager of the company’s Healthcare Information Technology business.

Dr. Michalis Papadakis is the CEO and co-founder of Brainomix. He leads the management team, commercial strategy, fund raising, and corporate partnerships. He has grown the company from the ground up, building the company’s global presence and has raised more than £30 million of private investment and public funding. When he founded Brainomix he was the Scientific Director of the preclinical stroke lab at the University of Oxford. He has a BSc Honours in Biochemistry from Imperial College London and a PhD in neurosciences from UCL School of Pharmacy. He has been an invited speaker at international scientific and innovation conferences.

James Dettore, senior strategist and founder of Brand Institute in 1993, has been instrumental in advancing BI’s hallmark of innovation and excellence. In 2004, he extended this legacy by establishing Drug Safety Institute (DSI), which has since become a premier company known for providing unparalleled expertise and cutting-edge regulatory services, setting the industry standard.

Mr. Dettore is an alumnus of the Harvard University Graduate School of Business Administration and currently serves on the Executive Committee of the Harvard University New York Chapter Owner & President Management Program (OPM).

In recognition of BI and DSI’s unwavering support of the pharmacy profession and commitment to patient safety, Mr. Dettore was inducted into the Phi Lambda Sigma Pharmacy Leadership Society in 2020. With over three decades of experience in brand management, he has held key positions at renowned organizations, including PepsiCo, J. Walter Thompson, Hilton International Hotels, and Ralph Lauren.

Mr. Dr. Giovanni Caforio, M.D., serves as the Chief Executive Officer of Bristol Myers Squibb Australia Pty Ltd. Dr. Caforio serves as Chief Operating Officer at Medarex, Inc. He has responsibility for leading a fully integrated worldwide commercial organization and Medarex-wide functions of Enterprise Services and Global Manufacturing & Supply. He has been the Chief Executive Officer of Bristol Myers Squibb Company since May 5, 2015. He served as Chief Operating Officer Myers Squibb Company since June 9, 2014 and also served as its Chief Commercial Officer and Executive Vice President since November 13, 2013. Dr. Caforio leads the Bristol-Myers Squibb Company’s pharmaceutical business in the U.S. He served as Chief Commercial Officer at Medarex, Inc. Dr. Caforio served as the President of U.S. Pharmaceuticals at Bristol Myers Squibb Company since October 2011. He served as Senior Vice President of U.S. Oncology, Worldwide Pharmaceuticals at Bristol Myers Squibb Company from 2007 to 2009. He served as Senior Vice President of Global Commercialization, Oncology and Immunology at Bristol Myers Squibb from January 2011 to October 2011 and its Senior Vice President of Oncology, Global Commercialization from 2009 to 2010, where he helped re-establish Bristol Myers Squibb as a leader in Oncology, including the launch of YERVOY™, the Bristol Myers Squibb’s innovative immuno-oncology medicine for metastatic melanoma. As a leader, his focus is on developing talented leaders with the diverse experiences and competencies needed for the continued success of the Bristol-Myers Squibb Company. He joined Bristol-Myers Squibb in 2000 as Vice President and General Manager of Italy, in the Worldwide Medicines Group. In 2001, he assumed added responsibility for Greece and Israel, and then all of South East Europe in 2003. Since 2004, he served as Senior Vice President of European Marketing and Brand Commercialization of Bristol Myers Squibb. Since 2007, he served as Senior Vice President of U.S. Oncology of Bristol Myers Squibb. Prior to joining Bristol Myers Squibb, he spent 12 years with Abbott Laboratories in a number of leadership positions. He has been a Director of Bristol Myers Squibb Company since June 9, 2014. He served as a Director of Capital Health System, Inc. until June 17, 2016. Dr. Caforio holds an M.D. from the University of Rome.

Ken Keller is President and CEO of Daiichi Sankyo, Inc. He also leads the U.S. Business and serves as a member of Daiichi Sankyo’s Global Management Committee. Mr. Keller joined Daiichi Sankyo Inc. in 2014.

Through his work with Daiichi Sankyo, and prior to that with Amgen Inc., Mr. Keller has more than 30 years of experience in the pharmaceutical industry. He has led multi-billion dollar businesses in the U.S. and Europe.

Through leadership roles in multiple markets, across cultures and within different healthcare systems, Mr. Keller has successfully launched numerous biologic products in therapeutic areas ranging from oncology to bone health to nephrology to inflammatory diseases, transformed businesses, and delivered sustainable revenue and profit growth

Since joining Daiichi Sankyo, Inc., Mr. Keller has shifted the structure of the U.S. business to focus on launching multiple oncology therapeutics in the coming years. He is known for his inclusive leadership approach and his passion for bringing innovative drugs to patients in need.

Mr. Keller is a member of the PhRMA Board of Directors and was previously a board member of the Association of the British Pharmaceutical Industry. He holds a Bachelor of Science degree in Business from Saint John’s University and a Master of Business Administration degree from Loyola Marymount University.

Jake Van Naarden serves as executive vice president of Eli Lilly and Company and president of Loxo at Lilly. In this role, Jake oversees all aspects of oncology spanning discovery through commercial. Jake joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. Following the acquisition, Jake played a key role in establishing the Loxo at Lilly research and development program. In his earlier roles, Jake worked in various biotechnology investing, operational, and advisory capacities, including positions with HealthCorManagement, Aisling Capital, and Goldman Sachs. Jake received his A.B. degree in molecular biology from Princeton University.

A respected veteran with nearly 28 years in the clinical research services industry, John Potthoff, Ph.D., has directed major business for a number of companies.

Potthoff’s career began with a series of executive roles involving increasing responsibility at PPD. After seven years, he left to become the founder and CEO of Tanistry, Inc., a contract research organization focused on the central nervous system. After selling Tanistry to INC Research in 2001, he joined INC Research, an 11-year career step that culminated in the role of COO.

Following his success at INC Research, Potthoff assumed the position of CEO at Theorem Clinical Research in 2011. In four years, he doubled its revenue, sales, backlog, and earnings before selling to Chiltern International in 2015.

Potthoff is NACD Directorship Certified and currently serves on the board of directors of Chembio (NASDAQ: CEMI) and previously served on the board of directors for Chiltern, Advarra, and Synteract.

As President of EMD Serono and Global Head of the Innovative Medicine Franchises for Merck KGaA, Darmstadt, Germany, Andrew Paterson leads the North American biopharmaceutical business across the U.S. and Canada in addition to leading the global oncology and neurology & immunology specialty medicine franchises for the healthcare business of Merck KGaA, Darmstadt, Germany.

Prior to this, Paterson served as Senior Vice President, Head of U.S. and Global MS Franchise, where he oversaw all commercial operations for the franchise in the US and also led global marketing efforts for our MS therapies.

In his 23 years with the company, Andrew has held positions in Local, Regional and Global commercial functions across a variety of therapeutic areas including Neurology, Endocrinology, Fertility and Cardio-vascular.

He began his career with Merck KGaA, Darmstadt, Germany in 1998 as a Medical Sales Representative in the UK. He subsequently took on roles of increasing responsibility including first line Sales Manager, Marketing Manager and Business Unit Director. Global and Regional leadership roles followed. Most recently, his focus was on the preparation and execution of the global launch of a new therapy in MS and progressing pipeline therapies toward commercialization.

Paterson holds a BSc (Hons) in Biological Science from the University of Edinburgh and an Executive MBA from Ashridge Management College.

Dr. Brian Alexander was named Chief Executive Officer of Foundation Medicine in March 2021. He previously served as the company’s Chief Medical Officer since 2019, and is a practicing radiation oncologist specializing in neuro-oncology at Dana-Farber/Brigham and Women’s Cancer Center, and a Senior Lecturer at Harvard Medical School.

Since joining the company in September 2018 as a Senior Vice President of Clinical Development, Dr. Alexander has played a pivotal leadership role in Foundation Medicine’s decision insights strategy, helping oncologists, both in community and academic settings, determine the right treatment, at the right time, for each unique patient. Under his leadership, Foundation Medicine’s medical team has expanded its molecular tumor board program to include over 90 leading oncology centers globally, launched a cross-functional genomics and health disparities effort, and has developed hundreds of studies and publications to advance the clinical utility of genomic profiling.

Dr. Alexander was the founding director of the Program in Regulatory Science at the Dana-Farber Cancer Institute and the Harvard/MIT Center for Regulatory Science. He also co-founded the Global Coalition for Adaptive Research, a non-profit organization focused on clinical trial innovations to accelerate the discovery and development of cures for patients with rare and deadly diseases, and served as chair of the FDA/Project Datasphere task force on external control arms. Dr. Alexander is an affiliated researcher at the MIT Laboratory for Financial Engineering and affiliated faculty of the Harvard Kennedy School Healthcare Policy Program. He was named to Boston Magazine’s “Top Doctors List” in 2019, 2020, and 2021.

Previously, Dr. Alexander served as a White House fellow and Special Assistant to the Secretary of Veterans Affairs, where he helped prepare the VA for the transition of administrations, worked to develop a public reporting system for quality, and served as a health policy advisor to the Secretary. Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. He was also a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education.

Dr. Alexander’s research interests focus on innovations in clinical evidence generation to support the development of therapeutics, biomarkers, and novel endpoints. He co-authored a book titled “Diagnostic Test Interpretation and Reasoning Under Uncertainty,” detailing the use of Bayesian approaches to clinical decision-making. Dr. Alexander was the founding principal investigator of INSIGhT, a multi-institutional genomic biomarker-based Bayesian adaptively randomized trial for patients with glioblastoma. He is the recipient of the Burroughs-Wellcome Innovations in Regulatory Science Award for his work applying such approaches to clinical trial design.

Dr. Alexander received his B.A. from Kalamazoo College, M.D. from the University of Michigan Medical School, and M.P.H. from the Harvard School of Public Health. He completed his training in radiation oncology at the Harvard Radiation Oncology Program.

Adam Pellegrini is the Co-Founder and CEO of Jasper Health. In this role, Adam will grow Jasper into the leading platform enabling cancer patient navigation, management, and care. Previous to Jasper, Adam was the Senior Vice President of Virtual Care and Consumer Health Innovations for CVS, Aetna and Caremark, leading new product ideation and execution across the portfolio. Before CVS, Adam was the SVP and General Manager of Fitbit Health Solutions which was tasked with helping Fitbit connect its products, information, data and insights with employers, health plans and hospital systems in new and innovative ways.

Pellegrini brings more than 21 years of experience across multiple sectors of the healthcare industry including consumers, providers, insurers, health technology and nonprofits. Before Fitbit, Adam created the Digital Health strategy for Walgreens Boots Alliance as the Vice President of Digital Health, responsible for revolutionizing how the global chain approached omni-channel digital healthcare, including advancing the company’s integration with wearables, launching telemedicine and advancing their core digital pharmacy platforms. As part of his work with Walgreens, his team led the largest retail mHealth integration of more than 1 million connected devices and launched the company’s first integration of wearables, including Fitbit devices, with its Balance Rewards program which rewards customers for making healthy choices.

Prior to WBA, Pellegrini led teams building the future of Digital Health including Microsoft HealthVault and HealthyCircles and was the first online strategy leader for the American Cancer Society. Adam started his career in the U.S. Army as an Operating Room Technician also working in aviation medicine, as an emergency room technician and leading occupational medicine initiatives for major health systems.

Officially named president in September after being unanimously selected as the sole finalist by the UT System Board of Regents, Peter WT Pisters, MD previously served MD Anderson in faculty and leadership roles for more than 20 years. Most recently, he was president and chief executive officer of the University Health Network (UHN) in Toronto, Canada.

Pisters oversaw more than 14,000 employees and a $400 million research enterprise at UHN, Canada’s largest hospital-based research program, beginning in January 2015. Prior to his appointment at UHN, he was vice president for MD Anderson’s regional care system, comprising multiple Houston-area locations.

Pisters initially joined MD Anderson’s faculty in 1994 as assistant professor of Surgery, rising to full professor with tenure in 2004. His specialties are sarcoma and gastrointestinal cancer, and he remains a board-certified surgeon. He also holds a master’s degree in health care management from Harvard University.

Elcin Barker Ergun worked in Global, Regional and Local leadership roles in Pharma Industry for more than 20 years including Commercial, Finance and Innovation leadership.

Elcin is Member of the Board of Directors and CEO of Menarini Group as of September 2019 based in Florence.

Prior to that, she was EVP, President of New Businesses, Merck KGaA Healthcare based in Boston responsible for an entity carrying out external R&D collaborations to create new businesses with estimated peak sales of $5-9billion.

Before that, she was EVP, Head of Global Commercial for Merck Serono based in Germany, where she was responsible for a P&L of €4.5 billion and over 5,000 people and achieved significant business and leadership transformation across global operations.

Prior to that, she was SVP, Head of Intercontinental Region comprising of 69 countries across Middle East, Africa, Turkey, Russia/CIS with a P&L of €650 million. During her term, topline grew by 40%. Prior to that, she was Managing Director of Turkey, where she started up and grew the operation to become a strong specialty player attaining market leadership in each key business.

In her earlier career, Elcin held several finance roles as subsidiary CFO Smithkline Beecham and as subsidiary CFO for Honeywell where she was responsible for full spectrum of finance, accounting, treasury, tax and reporting functions. She also spent one year in UK at Northern European HQ of Honeywell leading marketing and supply chain projects. She started her career as a software engineer and worked for ITT in Amsterdam for 5 years in IT Management.

Rob Davis is chief executive officer and president of Merck.

Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.

Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021 and CEO and a member of the board of directors on July 1, 2021.

Prior to joining Merck, Rob was corporate vice president and president of Baxter’s Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s Renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.

Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.

Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.

Belén Garijo is Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. She joined the company in 2011 as Chief Operating Officer of the Biopharma business, becoming President and CEO of Healthcare in 2015. In July 2020, Belén Garijo was appointed Vice Chairman of the Executive Board and Deputy CEO in addition to her role as CEO of the Healthcare business. She moved from Deputy CEO to CEO in May 2021.

Under her leadership, Healthcare at Merck KGaA, Darmstadt, Germany, has become a key player in the area of oncology, immunology and immuno-oncology, after the profound repositioning of the portfolio, the reorganization of R&D and the transformation of the commercial model. Belén Garijo has forged two major global alliances to further contribute to the portfolio’s maximization. She has also focused on globalization by expanding the business to growth markets as well as to Japan and the U.S.

Before joining Merck, Belén Garijo served as the Senior Vice President of Global Operations Europe at Sanofi-Aventis and Global Integration Leader of Genzyme after its acquisition by Sanofi. She previously held several local and global executive positions, both in R&D and commercial, at various companies at the forefront of the Healthcare sector.

She started her career as a practicing physician at La Paz hospital in Madrid before moving to the pharmaceutical industry. She is a medical doctor, specialized in clinical pharmacology.

Reshema Kemps-Polanco is Executive Vice President and US Head, Novartis Oncology, responsible for the commercialization of innovative cancer medicines, including complex platforms such as cell and gene therapy, and radiopharmaceuticals. With over 20 years of U.S. and global healthcare experience, she is pursuing a transformational growth strategy to sustain a leading position in the world’s largest healthcare market across oncology and hematologic diseases.

Reshema returned to Novartis in 2021 after spending seven years at Johnson and Johnson, where she served as President of Janssen’s Cardiovascular and Metabolism Unit in the U.S. and concurrently as President, Janssen Pharmaceuticals, Puerto Rico. Prior positions at Janssen include serving as Vice President across multiple roles in the U.S., as well as the Global Oncology organization. Before joining Johnson and Johnson, Reshema spent 15 years at Novartis where she led multiple commercial teams across oncology and specialty business units.

Reshema is a board member of the Healthcare Leadership Council, a coalition of chief executives focused on policies that make quality healthcare accessible to all Americans.

Reshema earned an M.B.A from Rutgers University, and M.A. in Industrial/Organizational Development from Louisiana Tech University and a B.A. from the University of Louisiana at Monroe.

Heather Cianfrocco is president of Optum. Cianfrocco joined UnitedHealth Group in 2008 where she held numerous leadership roles. She previously served as chief executive officer of Optum Rx and chief executive officer for Optum’s Health Services where she was responsible for behavioral health benefits, population health solutions and medical benefit management. Before that, she was chief executive officer of UnitedHealthcare Community & State, senior vice president of Health Advancement and Clinical Transformation for UnitedHealthcare Medicare & Retirement, and chief executive officer of state and regional health plans. In addition, she was a former member of the United Health Foundation Advisory Board.

Prior to UnitedHealth Group, Cianfrocco worked in private legal practices in Pittsburgh where she concentrated on corporate and securities law, representing health care entities in mergers and acquisitions. She earned a master’s degree in health care delivery science from Dartmouth College and a J.D. from Duquesne University School of Law.

Dr. Maya Said is the Founder and CEO of Outcomes4Me, a health technology company focused on providing patients diagnosed with cancer and other chronic diseases with personalized treatment options as well as outcomes information. Maya spent the last 20 years working in healthcare, primarily in the pharmaceutical industry with a focus on increasing innovation and access. Despite her extensive experience with healthcare systems globally, it wasn’t until she first became a patient herself that she realized much more can be done to improve outcomes and better serve the needs of patients. An engineer and scientist, she strongly believes that technology combined with early patient input can address many of the gaps patients experience today in navigating the healthcare system. Her conviction that technology-based solutions that empower patients can lead to better outcomes led her to create Outcomes4Me.

Prior to founding the company, she spent many years as a senior pharmaceutical executive at both Novartis and Sanofi leading global functions including: Market Access, Policy, R&D Strategy, and Business Development. Earlier in her career, Maya was a Partner at the Boston Consulting Group and a founding member of its Strategy Institute.

Maya trained at the Massachusetts Institute of Technology (MIT), earning dual degrees in Biology and Electrical Engineering and Computer Science (EECS) with a minor in Economics. She also holds a Master of Science in Toxicology, a Master of Engineering in Electrical Engineering, and Computer Science, and a Doctor of Science in Electrical Engineering, Computer Science, and Systems Biology, all from MIT. She has authored numerous scientific and strategy articles and was honored with the Carlton E. Tucker award for teaching excellence, the Department Head Recognition Award for major contribution to the EECS Department at MIT, and the Burchard Scholar for excellence in humanities and social sciences.

Albert Bourla became Chief Executive Officer on January 1, 2019.

In his previous role, Albert was Pfizer’s Chief Operating Officer (COO), overseeing the company’s commercial strategy, manufacturing and global product development functions. Prior to being named COO, Albert was the Group President of Pfizer Innovative Health, responsible for the Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines and Consumer Healthcare business groups. He also created the Patient and Health Impact group, dedicated to developing solutions for increasing patient access, demonstrating the value of our innovations and ensuring broader business model innovation.

Albert has more than 25 years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines, including Group President of Pfizer’s Global Vaccines, Oncology and Consumer Healthcare business and President and General Manager of Pfizer’s Established Products business.

Albert joined Pfizer’s Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of U.S. Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing; supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit’s R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East, and in 2009, he assumed additional responsibilities for Asia and Pacific.

Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is a member of the Board of Directors of Pfizer Inc., the Pfizer Foundation and the Partnership for New York City.

Steve Rusckowski is Chairman, President and Chief Executive Officer of Quest Diagnostics. Since joining Quest Diagnostics as President and Chief Executive Officer in May 2012, Mr. Rusckowski has focused on transforming the company, based on its compelling vision of “Empowering better health with diagnostic insights.” Under his leadership, the company has refocused on its core diagnostic information services business, sold non-core assets, delivered disciplined deployment, including share repurchases and acquisitions, and simplified its organizational structure to better serve customers by removing complexity, speeding decision making and empowering employees. He was elected Chairman of the Board in December 2016.

Prior to joining Quest Diagnostics, Mr. Rusckowski was CEO of Philips Healthcare, which became the largest unit of Royal Philips Electronics under his leadership. He joined Philips in 2001 when it acquired the Healthcare Solutions Group he was leading at Hewlett-Packard/Agilent Technologies. Mr. Rusckowski is a member of the Board of Directors of Project Hope, a global health education and humanitarian assistance organization. He is also a member of the Board of Directors of the American Clinical Laboratory Association, and served as its Chairman from 2014-2017.

Mr. Rusckowski earned a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute and a Master of Science degree in Management from the Massachusetts Institute of Technology’s Sloan School of Management.

Teresa Graham started with Genentech in 2005 in product management. She became a Sales Manager in 2010 before taking over the Marketing Director role for Rituxan Immunology and subsequently for Actemra. Her responsibilities further expanded in 2013 when she became Senior Director for Field Reimbursement Management and then Lifecycle Leader for Actemra. By 2017, she was leading major aspects of the portfolio for Genentech until she was appointed to her current role in 2019 and relocated to Basel, Switzerland. A graduate of The George Washington University with a BBA in Business, Economics, and Public Policy, she is also a Global Board Member for the Healthcare Businesswomen’s Association, where she has served in multiple capacities for more than a decade.

Tim J. Gabel became RTI International’s president and chief executive officer in 2022. Before becoming CEO in 2022, he served 10 years as executive vice president of Social, Statistical, and Environmental Sciences, the largest business unit within RTI.

As head of SSES, Mr. Gabel successfully grew the group from $391M to $667M in annual sponsored research, organically expanding existing divisions while overseeing the integration of acquisitions and development of strategic partnerships. Under Mr. Gabel’s executive oversight, a staff of 3,000 nationally recognized researchers, technologists, methodologists, and data scientists conducted over 1200 projects per year. Although varying in size and scope, common among those projects were complex multi-year, multi-million-dollar research studies that enabled federal, state, local, and international governments to make better policy decisions for all its citizens in the areas of health, education, justice, environment, and economic development. The number of RTI Fellows (RTI’s most accomplished scientists) in SSES nearly doubled under his leadership, and the organization witnessed a dramatic increase in major media outlet citations of their work.

A long-tenured RTI employee, Mr. Gabel has served at every level of RTI leadership, guiding various divisions and operating units to innovation-driven growth by maintaining a focus on operational excellence, client centricity, and a high commitment to quality.

Mr. Gabel is a member of the American Statistical Association, American Association for Public Opinion Research, and American Public Health Association. He co-edited the book The Essential Role of Language in Survey Research, published in 2020 by RTI Press. He holds adjunct appointments at the University of Wyoming and the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.

Mr. Gabel serves his community in a variety of volunteer roles, including board member of Go Global NC, board member of the United Way of North Carolina, Tocqueville Society member of the United Way of Alamance County, and member of the Board of Visitors for the University of Wyoming College of Arts & Sciences.

Mr. Chris Sarchi is responsible for all aspects of marketing and commercialization of oncology and transplant products at Sanofi Genzyme for North America.

Mr. Sarchi joined Sanofi Genzyme in December 2017, following a successful career in the pharmaceutical and biotechnology industry spanning over 25 years. During this time, he held various leadership positions in sales, marketing, strategic planning and new product development, as well as business unit leadership covering multiple therapeutic areas.

Prior to his current role, Mr. Sarchi was the Vice President and BU Head of Oncology and Biosimilars at Boehringer Ingelheim from 2013 to 2018. At BI, he was responsible for the initial build out of the oncology field commercial team. Mr. Sarchi has had additional leadership opportunities and experiences during his time at GSK, as well as Roche/Genentech.

As the CEO of SAS, the world’s leading business analytics software vendor, Jim Goodnight has led the company since its inception in 1976, overseeing an unbroken chain of revenue growth and profitability unprecedented in the industry. He is recognized globally for being a trailblazer among companies that top great workplace rankings, including being No. 1 on several country and multinational lists. Harvard Business School named Goodnight a Great American Business Leader, and he was named one of America’s 25 Most Fascinating Entrepreneurs by Inc. magazine. A champion of education reform, Goodnight sees education as critical to the success of individuals, organizations and nations.

Teresa Bitetti is President of the Global Oncology Business Unit. She is responsible for oncology business activities in ten countries, including the U.S., Japan, U.K., Ireland, Germany, France, Italy, Spain, Portugal, and Canada.

Before joining Takeda, Teresa Bitetti was the Senior Vice President, Head of Worldwide Oncology Commercialization at Bristol-Myers Squibb. In this role, Teresa significantly enhanced the long-term strategic direction of the immuno-oncology portfolio. In addition, she further enhanced the model of collaboration with the R&D team to ensure the long-term success of its marketed and pipeline Oncology products. In the company, some of her key leadership roles have included Senior Vice President and Head of U.S. Oncology, President and GM of BMS Canada, and Worldwide Head of the BMS Virology business.

Prior to joining Bristol-Myers Squibb, Teresa held various roles of increasing responsibility at Mobil Oil Corporation, where she was part of the Capital Markets Group and was responsible for the investment of Mobil’s worldwide pension assets.

Over Teresa’s 20+ year career, she has been highly recognized for her adept ability to mobilize teams to deliver exceptional performance. Her notable awards include Medical Marketing Association 2003 Pharmaceutical Marketer of the Year Award and Medical Marketing & Media 2016 Hall of Femme Honoree.

Teresa holds a BA in Classical Civilization from Wellesley College and an MBA in Finance from Darden School of Business at University of Virginia.

Since 2009, Major General Granger has been the President and CEO of THE 5Ps, LLC, a health care, education, and leadership consulting organization in Colorado. Prior to his retirement from the US Army in 2009, Dr. Granger served as the Deputy Director and Program Executive Officer of the TRICARE Management Activity, Office of the Assistant Secretary of Defense (Health Affairs) in Washington, DC.

In that role, he was the principal advisor on health plan policy and performance at the Department of Defense. His experience, background, training, and expertise has required the building of strong, value-based relationships. He acquires clear guidelines to assess and determine “best value” and determines a process to ensure clear requirements and criteria to manage relationships to measurable, accountable outcomes.

Dr. Granger oversaw the acquisition, operation, and integration of TRICARE/DOD’s managed care program within the Military Health System, leading a staff of 1,800 in planning, budgeting, and executing a $22.5 Billion Defense Health Program.
Prior to joining TRICARE Management Activity, MG Granger led the largest U.S. and multi-national battlefield health system in our recent history while serving as Commander, Task Force 44th Medical Command and Command Surgeon for the Multinational Corps Iraq. He has led at every level of the Army Medical Department, with previous assignments across the United States, Europe, and Iraq.

Dr. Granger has received numerous awards, decorations, and honors, including the Defense Superior Service Medal, the Legion of Merit with three oak leaf clusters, the Bronze Star Medal, and the Meritorious Service Medal with four oak leaf clusters. He is board-certified by the American Board of Internal Medicine and the Board of Hematology and Oncology, certified Physician Executive by the Certifying Commission in Medical Management, certified by the American College of Healthcare Executives, and Certified in Medical Quality by the American Board of Medical Quality. CERT-certificate in Cybersecurity Oversight from Carnegie Mellon University, certified in Healthcare Compliance by HCCA and is a certified Compliance Officer by AAPC.

Dr. Wei He is Inventor, Founder & CEO of Zhejiang DTRM Biopharma Co. Ltd. (American-Chinese Joint Venture founded on November 11th, 2011 in China) and Zhejiang DTRM Biopharma LLC (Registered in Delaware, USA). DTRM Biopharma is a clinical-stage company conducting simultaneously clinical trials in USA and China, with patent-protected clinically differentiated target therapy and first-in-class oral doublet and triplet therapies along with $73 million raised in 6-years. Dr. He is the inventor and a co-inventor of 40 granted US patents and 3 issued patents in China, with pending patents in other Countries and Areas.

Prior to founding DTRM Biopharma, Dr. He spent 20 years with Morningside Venture, Adolor Corporation, Vitae Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, Aventis Pharmaceuticals, and Rhône-Poulenc Rorer Pharmaceuticals. Dr. He has a proven track record in the area of drug discovery, project management, and business development with increased responsibilities to leadership positions. Dr. He has discovered & developed many novel clinical drug candidates for treating cancers, cardiovascular diseases, gastroenterology disorders and diabetes including FDA-approved dual targeting medicine Viberzi (Eluxadoline or，JNJ27018966). Dr. He’s inventions and licensing have contributed to the L&A deals ranging from $300 million to $1.5 billion (Vitae-Boehringer Ingelheim, Adolor-Cubist, Furiex-Forest Lab/Allergan).

Dr. He was awarded with a B.S. degree in Chemistry from Peking University in 1985, and a member of the elite Chemistry Graduate Program sponsored by U.S. and China. Dr. He earned a Ph.D. degree in Chemistry followed by a post-doctoral research at The Ohio State University.

Dr. He is committed to develop better therapies for cancer patients in part due to his father died of cancer at age of 65